Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review.
The clinical results presently available on the use of daunorubicin (DNR)-DNA and Adriamycin (ADR)-DNA are reviewed in light of the most recent experimental data regarding the anthracycline-DNA complexes. Three randomized trials indicate that ADR-DNA is superior to DNR-DNA in combination therapy for acute lymphoblastic leukemia, that DNR-DNA equals DNR in the treatment of acute nonlymphoblastic leukemia, and that ADR-DNA might be equal to ADR in the chemotherapy for anaplastic bronchogenic carcinoma. Increasing evidence suggests that the anthracycline-DNA complexes are less cardiotoxic than the corresponding free drugs.
D000818:Animals; D002648:Child; D004247:DNA / Q000627:therapeutic use*; D018736:DNA Adducts; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011897:Random Allocation
D018736:DNA Adducts; D004338:Drug Combinations; C020270:daunorubicin-DNA; C031902:doxorubicin-DNA; D004317:Doxorubicin; D004247:DNA; D003630:Daunorubicin